OBJECTIVE: To study whether the D2 Thr92Ala polymorphism-a genetic marker that is associated with reduced thyroid type 2 deiodinase (D2) activity, increased insulin resistance, and risk for type 2 diabetes-is associated with disrupted placental D2 activity and with glycemic control and gestational outcomes. DESIGN: Cross-sectional study. SETTING: Tertiary hospital in Brazil. PATIENT(S): Consecutive singleton-pregnancy patients, 18-45 years old. INTERVENTION(S): Clinical examination and genotyping of the D2 Thr92Ala polymorphism, with placental samples collected and assayed for D2 mRNA and activity. MAIN OUTCOME MEASURE(S): Glucose homeostasis and gestational outcomes. RESULT(S): A total of 294 patients were included in the study. The clinical and laboratory characteristics were similar among the D2 genotypes. No differences were observed in D2 placental mRNA levels, but D2 activity was decreased in patients with the Ala92Ala genotype (0.35 ± 0.15 vs. 1.96 ± 1.02 fmol/mg/min.). Newborn serum thyroid-stimulating hormone levels (TSHneo) did not differ according to maternal D2 Thr92Ala genotype. Also, maternal glucose control, insulin resistance evaluated by the homeostasis model assessment (HOMA-IR), and gestational outcomes did not differ across D2 genotypes. CONCLUSION(S): The D2 Ala92Ala genotype is associated with reduced placental D2 activity but is not associated with dysglycemia, increased insulin resistance, or worse gestational outcomes.
OBJECTIVE: To study whether the D2 Thr92Ala polymorphism-a genetic marker that is associated with reduced thyroid type 2 deiodinase (D2) activity, increased insulin resistance, and risk for type 2 diabetes-is associated with disrupted placental D2 activity and with glycemic control and gestational outcomes. DESIGN: Cross-sectional study. SETTING: Tertiary hospital in Brazil. PATIENT(S): Consecutive singleton-pregnancy patients, 18-45 years old. INTERVENTION(S): Clinical examination and genotyping of the D2 Thr92Ala polymorphism, with placental samples collected and assayed for D2 mRNA and activity. MAIN OUTCOME MEASURE(S): Glucose homeostasis and gestational outcomes. RESULT(S): A total of 294 patients were included in the study. The clinical and laboratory characteristics were similar among the D2 genotypes. No differences were observed in D2 placental mRNA levels, but D2 activity was decreased in patients with the Ala92Ala genotype (0.35 ± 0.15 vs. 1.96 ± 1.02 fmol/mg/min.). Newborn serum thyroid-stimulating hormone levels (TSHneo) did not differ according to maternal D2 Thr92Ala genotype. Also, maternal glucose control, insulin resistance evaluated by the homeostasis model assessment (HOMA-IR), and gestational outcomes did not differ across D2 genotypes. CONCLUSION(S): The D2 Ala92Ala genotype is associated with reduced placental D2 activity but is not associated with dysglycemia, increased insulin resistance, or worse gestational outcomes.
Authors: Wallace Klein Schwengber; Vitor Bock Silveira; Guilherme Moreira Hetzel; Amanda Robaina; Lucieli Ceolin; Marli Teresinha Camelier; Iuri Goemann; Roberta Rigo Dalla Corte; Rafael Selbach Scheffel; Renato Gorga Bandeira de Mello; Ana Luiza Maia; José Miguel Dora Journal: Metabolites Date: 2022-04-21
Authors: Sebastián Gutiérrez-Vega; Axel Armella; Daniela Mennickent; Marco Loyola; Ambart Covarrubias; Bernel Ortega-Contreras; Carlos Escudero; Marcelo Gonzalez; Martín Alcalá; María Del Pilar Ramos; Marta Viana; Erica Castro; Andrea Leiva; Enrique Guzmán-Gutiérrez Journal: PLoS One Date: 2020-11-24 Impact factor: 3.240